Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
International journal of cardiology（2023）
摘要
Dapagliflozin-SoC was cost-effective versus empagliflozin-SoC or SoC alone for treatment of HFrEF.
更多查看译文
关键词
Cost-effectiveness,Dapagliflozin,Empagliflozin,Heart failure with reduced ejection fraction
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要